Bioequivalence and Bioavailability Forum

Dear d_labes,

❝ Having in mind Stephen Senn's basic estimator approach:

❝ Calculate the difference (of log-transformed metrics) you are interested in via intra-subject contrasts and analyse them as sequence group stratified mean (intercept of an ANOVA with sequence as effect) goes along the same line. Senn calls this approach "simple and fairly robust", don't know exactly whatever robust here means.

Was this said in specific reference to equivalence crossover trials? I ask because I mainly think of Senn as the God of superiority statistics, while at the same time I reckon that for equivalence stats certain aspects are sometimes completely contrary to superiority stats. A good example is ITT which is the conservative population for superiority while the conservative population for equivalence is PP. I thus wonder if this robustness, whatever it is, applies equally to superiority and equivalence?